Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Dongguan People's Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07643636CT.gov Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML | — | Not Yet Recruiting | — | — | — |
NCT07651475CT.gov Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | — | Active Not Recruiting | — | — | — |
NCT07304232CT.gov Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML | — | Recruiting | — | — | — |
NCT07514936CT.gov Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | — | Recruiting | — | — | — |
NCT06451861CT.gov Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | — | Recruiting | — | — | — |
NCT06386302CT.gov Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06928376CT.gov A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | — | Recruiting | — | — | — |
NCT06220162CT.gov VAC Regimen for AML Patients Who Failed to Response to VA Regimen | — | Recruiting | — | — | — |
NCT06066905CT.gov A Study of Chidamide With AZA in MRD Positive AML After Transplant | — | Recruiting | — | — | — |
NCT06084819CT.gov Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT05951855CT.gov Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT06068621CT.gov Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05659992CT.gov Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05682755CT.gov Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | — | Recruiting | — | — | — |
NCT05603884CT.gov VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT06827899CT.gov Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | — | Recruiting | — | — | — |
NCT05270200CT.gov Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse | — | Recruiting | — | — | — |
NCT05305859CT.gov Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | — | Recruiting | — | — | — |
NCT05029141CT.gov New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05330364CT.gov Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT03985007CT.gov CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03031262CT.gov Efficacy and Safety of Chidamide in CBF Leukemia | — | Active Not Recruiting | — | — | — |
NCT02886559CT.gov Chidamide Plus DCAG for Relapsed/Refractory AML | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucidinostat (this asset) | Dongguan People's Hospital | P2 | B · 59 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Tucidinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 69 |
| Acute Lymphoblastic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucidinostat in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucidinostat-acute-myeloid-leukemia-2310
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →